Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. has engaged Haywood Securities Inc. to provide strategic investment advisory services, aiming to facilitate strategic partnerships and secure investments. The company is advancing its clinical trials, with several Phase 2B studies in progress for their lead drug MB22001, which has demonstrated promising results in treating depression with fewer side effects than traditional antidepressants.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
